stocks inplay

Аналитика NYSE на 30 сентября
 
Спайдер снижается перед открытием торгов на NYSE.  

• Европейские индексы на отрицательной территории.

 
SPY (внутридневной график)  снижение на   премаркете. Поддержка 167.50, сопротивление 168.00
 
 
Премаркет NYSE/NASDAQ:
Gapping up:

• In reaction to strong earnings/guidance: CRRS +7.8%.
• M&A news: ACTV +27.4% (Active Network to be acquired by Vista Equity Partners; stockholders to receive $14.50 per share), CHRM (Charm Communications announces receipt of 'going private' proposal priced at $4.70 per ADS).
• Other news: DCTH +30% (received Orphan Drug Designation for Treatment of patients with hepatocellular carcinoma ), ORB +8% (Orbital Sciences' unmanned cargo ship has reached the Intl space station, according to reports), QCOR +4.6% (still checking), NSPH +4.3% ( Study Demonstrates Significant Clinical and Economic Impact of Nanosphere's Verigene Blood Culture Test; Average per Patient Hospital Cost Savings of $60,000 and 22 Day Reduction in Length of Stay Observed), ZAZA +4% ( Announces Second Transaction with JV Partner to Acquire Additional Production and Further Develop Its Eaglebine/Eagle Ford East Assets), RMTI +3.1% (continued strength), CYTR +1.8% (reports new Aldoxorubicin data that demonstrates significant advantages over doxorubicin; provides additional updates on other Phase 2 studies ), HALO +1.8% (presents PEGPH20 Phase 1b clinical trial data that suggest a potential clinical benefit of using PEGPH20 with gemcitabine in patients with high levels of tumor associated hyaluronan), HNR +1.4% (announces exclusive negotiations to sell interest in Gabon for $137 mln in cash), AZN +0.6% (NKTR reported that partner AZN announced European Medicines Agency acceptance of Marketing Authorisation Application for Naloxegol), PMT +0.6% ( Hayman Capital Management discloses 5.1% passive stake in 13G filing out Friday after the close).

( Читать дальше )

Спайдер незначительно повышается перед открытием торгов на NYSE.  

• Европейские индексы на отрицательной территории.  

 

SPY (внутридневной график)  рост на   премаркете. Сопротивление: 170.00            Поддержка: 169.00                   
 
 
ПремаркетNYSE/NASDAQ:
Gapping up:

• In reaction to strong earnings/guidance: FUL +6.4%, BBBY +5.9%, NEO +5.1%, PRGS +3.9%, SNX +3.1%, MKC +0.5%.
• M&A news: USAK +35.1% (Knight Transportation (KNX) Proposes to Acquire USA Truck for $9.00 Per Share in Cash), FLOW +7% (o be acquired by American Industrial Partners for $4.05 per share), ALU +2.2% (Follow up to Nokia (NOK) is considering combination with ALU's mobile phone networks unit), BBRY +1.1% (Fairfax's CEO Prem Watsa confident Blackberry bid will succeed, according to reports).
• Select metals/mining stocks trading higher: AU +1.9%, ABX +1.4%, HMY +1.1%, NEM +1%, GOLD +0.9%, GFI +0.6%.
• Select solar related names showing strength: HSOL +3.3%, SOL +2.3%, YGE +2.2%, SCTY +1.2%, FSLR +1%, SPWR +0.9%.

( Читать дальше )

 
Спайдер снижается перед открытием торгов на NYSE.  

• Европейские индексы на отрицательной территории.

 
SPY (внутридневной график)  снижение   на   премаркете. Сопротивление: 165.00     Поддержка: 165.60
 
Премаркет NYSE/NASDAQ:
Gapping up:

• In reaction to strong earnings/guidance: SGOC +53%, LOW +4.4%, (Lowe's acquisition of Orchard Supply Hardware assets approved by bankruptcy court; Orchard CEO Mark Baker to be replaced by Richard D. Maltsbarger ), MSG +4.2%, EXXI +3.2%, LZB +1.2%.
• Other news: OINK +48.8% (signed an agreement with WUSHANG MART to sell cuts of its Tianli-Xiduhei black hog meat), INCY +22.2% (provides top-line results from Phase II proof-of-concept trial of ruxolitinib), INVE +14.3% (awarded a multi-year contract to provide cashless payment services at home matches of Berlin football club Hertha BSC in Olympiastadion Berlin), NAVB +11% (Navidea Biopharmaceuticals Announces Centers for Medicare & Medicaid Services (CMS) Issuance of Lymphoseek® Reimbursement Pass-Through C Code, Effective as of October 1, 2013), CLSN +9.2% (will present the official clinical trial results from the HEAT Study), GALE +6.6% (expands NeuVax intellectual property with European Allowance), RPRX +3.5% (Repros Reports 6 Month Bone Mineral Density Data From Ongoing Study ZA-303; Early evidence of improving bone mineral density in Androxal subjects), ALU +2.4% (still checking), DGX +2.1% (s increases share repurchase authority by $1 bln, bringing the total authorization to ~$1.3 bln), ODP +1.0% (Office Depot and Starboard reach Settlement; Starboard to withdraw proxy silicitation).

( Читать дальше )

 
Спайдер повышается перед открытием торгов на NYSE.  

• Европейские индексы на отрицательной территории.

 

SPY (внутридневной график)  рост   на   премаркете. Сопротивление: 166.00     Поддержка: 164.70             
 
 
Премаркет NYSE/NASDAQ:
Gapping up:

• In reaction to strong earnings/guidance: BBY +16%, URBN +9% (also upgraded to Outperform from Neutral at Wedbush), TSL +4%, HD +3.3%, JCP +2.9%, GWAY +1% (light volume), IRF +0.9%.
• Other news: ELTK +7.3% (secures a $4.2 mln investment from Nistek Ltd), FRO +6.9% (still checking), IBN +2.9% ( rebounding in early trade, now up 3.7% (down 21% over the past three tradng days), NVS +2.3% (light volume, Novartis AG receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis), LOW +2.1% (following HD results), TSLA +2.1% (National Highway Traffic Safety Administration has awarded the Tesla Model S a 5-star safety rating in every subcategory without exception), VOD +1.7% (still checking), GTXI +1.4% (after yesterday's 65%+ decline), GSK +1.3% (still checking), IOC +1.1% (after yesterday's 12% drop), NLY +0.9% (announces the Appointment of New Chief Financial Officer), AAPL +0.6% (Apple has hired former Nike (NKE) exec Jay Blahnik for its wearable unit, according to reports ), BAC +0.6% (higher despite reports that US Judge has endorsed fraud law use against BAC), CCL +0.6% (still checking), FSLR +0.5% (First Solar, Roseville Sign Contract for Lost Hills PPA), AMZN +0.4% (Amazon.com is increasing its warehouse building following competition from Ebay and Wal-Mart according to reports).

( Читать дальше )

Аналитика NYSE на 15 августа
Спайдер снижается перед открытием торгов на NYSE.  

• Европейские индексы на отрицательной территории.

 
SPY (внутридневной график)  снижение   на   премаркете. Сопротивление: 168.00     Поддержка: 167.00
 
Премаркет NYSE/NASDAQ:
Gapping up:

• In reaction to strong earnings/guidance: SPPR +11%, (also announced 1-for-8 reverse stock split;) DDS +6.9%, NTES +5.9%, NTES +5%, EARN +4.8%, A +3.8%, EL +2.1%, GK +1.7%, KSS +1.3%, SA +1%.
• M&A news: VLTR +54.1% (to be acquired by Maxim Integrated (MXIM) for $23/share), SIRI +0.5% (enters into a definitive agreement to acquire the connected vehicle services business of Agero for $530 mln in cash.
• Other news: ALVR +122.7% (still checking), BIOL +21.7% (to reduce total offering on Form S-3 to $5 mln from $30 mln; CEO says company is not in a liquidity crunch), INO +9.9% (malaria DNA vaccine demonstrates robust immune responses in animal models), SPEX +5.9% (retains the law firm of Skiermont Puckett to lead the commercialization effort of the co's patent portfolio acquired from Rockstar), FFHL +5.8% (announces receipt of notice of proposed public auction of controlling interest), RAD +2.9% (Greenlight Capital takes a share stake of 20.2 mln), JCP +1.6% (DailyMail discusses speculation that Bill Ackman will soon be working with PE firms to take JCP private at 'substantial premium', while George Soros wants to double his stake), DF +1.5% (announced 1-for-2 reverse stock split), MPWR +1.4% (Federal Circuit upholds $9.5 mln attorneys' fee and cost award to MPWR).

( Читать дальше )

 
Спайдер снижается перед открытием торгов на NYSE.  

• Европейские индексы на положительной территории.

 
SPY (внутридневной график)  снижение   на   премаркете. Сопротивление: 169.75    Поддержка: 169.00
 
Премаркет NYSE/NASDAQ:
 
Gapping up:

• In reaction to strong earnings/guidance: PETS +8.2%, XRS +4.2%, FDML +3.9%, PHG +3.7%, UBS +3.3%, HAL +1.6%.
• M&A news: NAFC +27% (Nash Finch and Spartan Stores (SPTN) enter into a definitive merger agreement; NAFC shareholders will receive a fixed ratio of 1.20 shares of SPTN common stock), SPTN +20.3%.
• Select EU financial related names showing strength following bte UBS guidance : CS +1.8%, BCS +1.8%, DB +1.6%.
• Select metals/mining stocks trading higher: SLW +5%, ABX +4.8%, GDX +4.6%, IAG +4.5%, GFI +4.2%, GG +4.1%, SLV +3.9%, NEM +3.7%, HMY +3.6%, AU +3.5%, AG +2.9%, GLD +2.2%.
• Select semiconductor related names showing early strength: CY +3.4%, TSEM +2.6%, MU +1%, ARMH +0.9%, 
• Other news: HIMX +36.9% (signs technology investment agreement with Google (GOOG)), BCRX +13.8% (successfully completes its Phase 1 clinical trial of BCX4161; initiates Phase 2), SLTM +8.7% (cont strength from Friday, blog suggesting potential acq candidate for VRX), TROV +6.5% (Co's Urine-based cancer detection technology validated), MSFT +1.1% (article suggesting co may give activist ValueAct seat on Board), FTEK +0.8% (awarded air pollution control orders totaling $6.4 mln), RDS.A +0.8% (to Boost Deepwater Production in Brazil; Decision to move forward with two projects at existing developments enhances offshore portfolio).

( Читать дальше )

Оригинал тут.

Неделя начинается прямо таки весело. На душе весна. А все почему? Потому что есть AFFY у нас. Говорят, что плохо наживаться на другом несчастье, но бизнес -есть бизнес. Тут нет места морализму. Видишь ситуацию — используй, раз ничего изменить не можешь.
 
Вот собственно оригинал новости по AFFY
Affymax and Takeda Pharmaceutical (TKPYY) decide to voluntarily recall all lots of OMONTYS Injection Price: 16.52 Change:
Affymax (AFFY) and Takeda Pharmaceutical (TKPYY) decided to voluntarily recall all lots of OMONTYS Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal. The companies have been working actively with the FDA which has indicated its agreement with this decision. The companies have also issued a letter to health care professionals indicating that no new or existing patients should receive OMONTYS. To date, fatal reactions have been reported in approximately 0.02% of patients following the first dose of intravenous administration. The reported serious hypersensitivity reactions have occurred within 30 minutes after such administration of OMONTYS. There have been no reports of such reactions following subsequent dosing, or in patients who have completed their dialysis session.
Если быть кратким, то компания совместо со своим партнером Takeda Pharmaceutical отзывает все выпуски препарата OMONTY. Причина — гиперчувствительность, включающая анафилаксию (кто смотрел Хауса, поймут:).х


( Читать дальше )

Наконец — то, руки дошли до отчетов. Подобрался вплотную к двух самым интересным секторам — Services и Technology. Скажу сразу — устал смотреть эти акции и делать скриншоты. Движений действительно много, тут редко встречаются акции, которые не реагируют на отчет.
 
Поехали, Services.Гигантов в этом секторе нет (разве что Wall Mart), что собственно не удивительно. Компания, предоставляющая услуги имеет определенный потолок в своем развитии и капитализации. Ходят сервисные компании на отчетах прекрасно, главное тут наличие реальной ликвидности в акции.


( Читать дальше )

Рост на премаркете больше, чем на 100%

Возможен шорт на фоне фиксации прибыли.




Вот и сама новость:


Sarepta Therapeutics announces eteplirsen meets primary endpoint of increased novel dystrophin and achieves significant clinical benefit on 6-minute walk test after 48 weeks of treatment in phase iib study in duchenne muscular dystrophy Price: 14.99 Change:
Co today announced that treatment with its lead exon-skipping compound, eteplirsen, met the primary efficacy endpoint, increase in novel dystrophin, and achieved a significant clinical benefit on the primary clinical outcome, the 6-minute walk test (6MWT) over the placebo/delayed treatment cohort in a Phase IIb extension trial in Duchenne muscular dystrophy (DMD) patients. Eteplirsen administered once weekly at either 30 mg/kg or 50 mg/kg for 48 weeks (n=8) resulted in a statistically significant increase (p=0.001) in dystrophin-positive fibers to 47.0% of normal. The placebo/delayed treatment cohort, which had received 24 weeks of eteplirsen at either 30 mg/kg or 50 mg/kg following 24 weeks of placebo (n=4), also showed a statistically significant increase in dystrophin-positive fibers to 38.3% of normal (p=0.009). Eteplirsen administered once weekly at 50 mg/kg over 48 weeks resulted in an 89.4 meter benefit compared to patients who received placebo for 24 weeks followed by 24 weeks of treatment with eteplirsen in the open-label extension. Co is holding a call at 8:00 ET to discuss.